Abstract
Objectives
Rofecoxib was withdrawn from the market on 30 September 2004 following the results of a randomized controlled trial. Following this sudden decision, several controversies occurred in the literature to determine whether this adverse drug reaction (ADR) could have been detected earlier. The aim of this study was to investigate whether this kind of signal could have been seen using the French Pharmacovigilance Database before this date of rofecoxib withdrawal.
Methods
Using cases registered in the French Pharmacovigilance Database from May 2000 to December 2006, we applied the case–noncase method to “serious” thrombotic ADRs reported with oral formulations of rofecoxib or celecoxib in patients older than 15 years. Cases were all notifications of thrombotic ADRs [World Health Organization Adverse Reaction Terminology (WHO-ART) codes 1300] occurred under coxib (rofecoxib, celecoxib) and noncases all other reports registered in the database (whatever the drug). We calculated a cumulative odds ratio (OR) from 20 May 2000 to 31 December 2006, with a special interest for the period before the 30 September 2004.
Results
Among the 50,087 “serious” ADRs registered in the database during this period, 1,127 were thrombotic ones. Rofecoxib exposure was significantly associated with high values of odds ratio (OR) [4.2 (95% CI 1.97–8.61)] for thrombotic ADRs as early as the end of 2001. The values of ADR reporting ORs remained high (3.0–3.5) until 2006. For celecoxib, a significant trend occurred only from September 2004.
Conclusion
Despite the compulsory limits of the case/noncase methodology, this study found an association between rofecoxib exposure and the occurrence of “serious” thrombotic ADRs as early as the end of the first year of rofecoxib marketing in France. The association between celecoxib and the occurrence of such ADRs appears less clear. Our work also shows the potential use of careful analysis of pharmacovigilance databases (investigating, for example, cumulative values of risk) in the early identification of new ADRs.
Similar content being viewed by others
References
Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307–314
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528
Silverstein FE, Faich G Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247–1255
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102
Clark DWJ, Laton D, Shakir AW (2004) Do some inhibitors of COX-2 increase the risk of thromboembolic events ? Drug Saf 27:427–456
Montastruc JL, Lapeyre-Mestre M, Gony M, Lugardon S, Bagheri H (2004) Coxibs, which real therapeutic advance? Recent pharmacoepidemiological data. Therapie 59:201–205
Arellano FM (2005) The withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 14:213–217
Jüni P, Reichenbach S, Egger M (2005) COX 2 inhibitors, traditional NSAIDs and the heart. Br Med J 330:1342–1343
Nissen SE (2006) Adverse cardiovascular effects of rofecoxib. N Engl J Med 355:203–204
Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and bnon-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475–481
Strand V (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370:2138–2151
Montastruc JL, Sommet A, Lacroix I, Olivier P, Durrieu G, Damase-Michel C, Lapeyre-Mestre M, Bagheri H (2006) Pharmacovigilance for evaluating adverse drug reactions: value, organization and methods. Joint Bone Spine 73:629–632
Stricker BH, Tijssen JG (1992) Serum sickness-like reactions to cefaclor. J Clin Epidemiol 45:1177–1184
Egberts AC, Meyboon RH, De Koning FH, Bakker A, Leufkens HG (1997) Nonpuerpueral lactation associated with antidepressant drug use. Br J Clin Pharmacol 44:277–281
Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B (1998) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/noncase study in the French pharmacovigilance system database. Br J Clin Pharmacol 44:513–518
Egberts AC, Meyboon RH, Van Puijenbroek EP (2002) Use of measures of disproportionality in pharmacovigilance: three dutch examples. Drug Saf 25:453–458
Lugardon S, Lapeyre-Mestre M, Montastruc JL, The French Network of Regional Pharmacovigilance Centres (2004) Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/noncase study from the French Pharmacovigilance Database. Eur J Clin Pharmacol 60:673–677
WHO (1992) International monitoring of adverse reactions to drugs: adverse reaction terminology. WHO collaborating Centre for International Drug Monitoring, Uppsala
Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugsActualization of the method used in France. Therapie 40:111–118
Van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of underreporting on odds ratio. Stat Med 21:2027–2044
Wilson AM, Thabane L, Holbrook A (2004) Application of data mining data in pharmacovigilance. Br J Clin Pharmacol 57:127–134
Shakir SAW (2007) Thoughs on signal detection in Pharmacovigilance. Drug Saf 30:603–606
Hand DJ (2007) Principles of data mining. Drug Saf 30:621–622
Topol EJ (2004) Failing the public health – Rofecoxib, Merck, and the FDA. New Engl J Med 351:1707–1709
Mukherjee D, Nissen SE, Topol EL (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–957
Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029
Prescrire Rédaction (2002) Effets indésirables cardiovasculaires des coxibs. Rev Prescr 22:596–597
Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arrelano FM (2001) A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre Safety Database. Clin Ther 23:1478–1491
Layton D, Hughes K, Harris S, Shakir SAW (2003) Comparison of the incidence rates of thromboembolic events reported in patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 42:1342–1353
Layton D, Heeley E, Hughes K, Shakir SAW (2003) Comparison of the incidence rates of thromboembolic events reported in patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 42:1354–1364
Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA (2005) A comparison of reported gastrointestinal and thromboembolic events reported between rofecoxib and celecoxib using observational data. Drug Saf 28:803–816
Vu D, Murty M, McMorran M (2002) Selective COX-2 inhibitors: suspected cardiovascular/cerebrovascular adverse drug reactions. Can Adv Reactions News 2:1–3
Warmer TD, Mitchell JA (2008) COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371:270–273
Conflict of interest statement
None.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Sommet, A., Grolleau, S., Bagheri, H. et al. Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004?. Eur J Clin Pharmacol 64, 829–834 (2008). https://doi.org/10.1007/s00228-008-0497-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-008-0497-3